High humidity decreases symptomatic patent ductus arteriosus

Phase 2

Recruiting

• Conditions: extremely premature infant, patent ductus arteriosus; D062071, D004374

• Registration Number: JPRN-jRCT1032190068
• Lead Sponsor: Hirata Michisato

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-08-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Preterm infants at gestational weeks of 24 to 27 who admitted to neonatal intensive care unit at Yokohama city university medical center

Exclusion Criteria

congenital abnormality
severe asphyxia (APGAR score 4 points or less at 5 minutes)
twin to twin transfusion syndrome apparent at birth
birth at another hospital
birth from underage and unmarried mother

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of symptomatic patent ductus arteriosus within 7 days from birth

Secondary Outcome Measures

Name	Time	Method
Total amount of indomethacin administered until 14 days after birth.<br>Maximum ascent rate of serum sodium concentration until 7 days after birth or until the onset of the symptomatic patent ductus arteriosus.<br>The incidence of hypernatremia (Na > 145mEq/L) until 7 days after birth.